China Approves Sale of COVID-19 Symptom Relief Drugs for Korean Residents

[Asia Economy Beijing=Special Correspondent Kim Hyunjung] On the 22nd, the Korean Embassy in China announced that the Ministry of Industry and Information Technology of China has authorized the direct sale of 66,700 boxes of Lianhua Qingwen (蓮花淸瘟), a COVID-19 related medicine requested by Korean expatriate organizations such as the Beijing Korean Association.

These organizations recently hoped to purchase Lianhua Qingwen directly from the pharmaceutical company Shijiazhuang Yiling Pharmaceutical Co., Ltd., considering the difficulty in obtaining related medicines due to the rapid increase in COVID-19 infections. Lianhua Qingwen is known to be effective in alleviating COVID-19 symptoms. They had requested cooperation from the Korean Embassy in China for this purpose. After receiving cooperation requests for purchasing Lianhua Qingwen from Korean associations across various regions in China, the embassy assessed the demand for the medicine and sought cooperation from the relevant pharmaceutical company, the Ministry of Industry and Information Technology, and the Ministry of Foreign Affairs.

Subsequently, the Ministry of Industry and Information Technology of China permitted the sale of the requested quantity to our expatriates. The medicine began shipping on the evening of the 21st and the morning of the 22nd, and it is expected to arrive in various locations depending on local logistics conditions. In the case of the Beijing Korean Association, the secured quantity was received on the 22nd.

The Korean Embassy in China expressed high appreciation for the cooperation extended by the Ministry of Industry and Information Technology, the Ministry of Foreign Affairs, and Shijiazhuang Yiling Pharmaceutical Co., Ltd. for the health and lives of Korean expatriates. Furthermore, the embassy stated that it plans to express gratitude appropriately for this support.

This content was produced with the assistance of AI translation services.